| TMC Life Sciences (0101.KU) - Malaysia | |
| (1st) quarter ended Sep 30: | |
| Figures Are In Ringgit $(MYR.AU)$. | |
| 2024 | 2023 |
Revenue | 81,967,000 | 92,438,000 |
PreTax Profit | 4,459,000 | 20,143,000 |
Net Profit | 2,936,000 | 15,140,000 |
Earnings Per Share | 0.17 Sen | 0.87 Sen |
Dividend | 0.00 Sen | 0.00 Sen |
(END) Dow Jones Newswires
November 18, 2024 04:08 ET (09:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments